Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.69 |
| ▸ | CDK1 | P06493 | 8/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514802 | 0.90 | CDK2 (0.75) | CDK2CDK1KCNH2 | |
| SCHEMBL4203202 | 0.84 | CDK4 (0.54) | CDK2CDK1KCNH2 | |
| SCHEMBL4513970 | 0.82 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL4517750 | 0.81 | CDK2 (0.74) | CDK2CDK1KCNH2 | |
| SCHEMBL4505144 | 0.80 | CDK2 (0.81) | CDK2CDK1KCNH2 | |
| SCHEMBL21956065 | 0.78 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL30828080 | 0.78 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL1447467 | 0.78 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL1448447 | 0.78 | CDK2 (1.00) | CDK2CDK1KCNH2 | |
| SCHEMBL30828086 | 0.78 | CDK2 (0.80) | CDK2CDK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608639-B2 | Phenoxyether derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1675814-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037763-A1 | PHENOXYETHER DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | CDK2 4/4885CDK1 6/4885KCNH2 3837/4885 |
| US-20070037812-A1 | Such as 3-{4-[3-(4-Chloro-2- phenoxy-phenoxy)- phenoxy]-2-methyl- phenyl}-propionic acid; peroxisome proliferator activated receptor (PPAR); syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis | PPARA, PPARG, PPARD | CDK2 3578/4885CDK1 4667/4885KCNH2 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.